Based on the key measurements obtained from Elevation Oncology's financial statements, Elevation Oncology is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At this time, Elevation Oncology's Total Current Liabilities is fairly stable compared to the past year. Cash is likely to climb to about 71 M in 2025, whereas Other Current Liabilities is likely to drop slightly above 3.8 M in 2025. Key indicators impacting Elevation Oncology's financial strength include:
Investors should never underestimate Elevation Oncology's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Elevation Oncology's cash flow, debt, and profitability to make informed and accurate decisions about investing in Elevation Oncology.
Net Income
(43.19 Million)
Elevation
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Cash Ratio
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Begin Period Cash Flow
Issuance Of Capital Stock
Sale Purchase Of Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Capital Stock
Net Working Capital
Other Liab
Non Currrent Assets Other
Other Assets
Non Current Liabilities Other
Intangible Assets
Short Term Investments
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Gross Profit
Net Income From Continuing Ops
Cost Of Revenue
Reconciled Depreciation
Tax Provision
Probability Of Bankruptcy
Understanding current and past Elevation Oncology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Elevation Oncology's financial statements are interrelated, with each one affecting the others. For example, an increase in Elevation Oncology's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Elevation Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Elevation Oncology. Check Elevation Oncology's Beneish M Score to see the likelihood of Elevation Oncology's management manipulating its earnings.
Elevation Oncology Stock Summary
Elevation Oncology competes with Ocean Biomedical, Zura Bio, Enveric Biosciences, and Hepion Pharmaceuticals. Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York. Elevation Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 40 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Elevation Oncology's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Elevation Oncology's current stock value. Our valuation model uses many indicators to compare Elevation Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Elevation Oncology competition to find correlations between indicators driving Elevation Oncology's intrinsic value. More Info.
Elevation Oncology is rated # 3 in return on equity category among its peers. It is rated # 2 in return on asset category among its peers . At this time, Elevation Oncology's Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Elevation Oncology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Elevation Oncology Systematic Risk
Elevation Oncology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Elevation Oncology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-five with a total number of output elements of sixteen. The Beta measures systematic risk based on how returns on Elevation Oncology correlated with the market. If Beta is less than 0 Elevation Oncology generally moves in the opposite direction as compared to the market. If Elevation Oncology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Elevation Oncology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Elevation Oncology is generally in the same direction as the market. If Beta > 1 Elevation Oncology moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Elevation Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Elevation Oncology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Elevation Oncology growth as a starting point in their analysis.
Elevation Oncology January 31, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Elevation Oncology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Elevation Oncology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Elevation Oncology based on widely used predictive technical indicators. In general, we focus on analyzing Elevation Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Elevation Oncology's daily price indicators and compare them against related drivers.
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.